GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (FRA:9VC) » Definitions » Debt-to-Asset

ATAI Life Sciences NV (FRA:9VC) Debt-to-Asset : 0.08 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ATAI Life Sciences NV Debt-to-Asset?

ATAI Life Sciences NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.22 Mil. ATAI Life Sciences NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €18.92 Mil. ATAI Life Sciences NV's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €247.59 Mil. ATAI Life Sciences NV's debt to asset for the quarter that ended in Mar. 2024 was 0.08.


ATAI Life Sciences NV Debt-to-Asset Historical Data

The historical data trend for ATAI Life Sciences NV's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV Debt-to-Asset Chart

ATAI Life Sciences NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
- 0.02 - 0.05 0.07

ATAI Life Sciences NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.07 0.05 0.07 0.08

Competitive Comparison of ATAI Life Sciences NV's Debt-to-Asset

For the Biotechnology subindustry, ATAI Life Sciences NV's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ATAI Life Sciences NV's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ATAI Life Sciences NV's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where ATAI Life Sciences NV's Debt-to-Asset falls into.



ATAI Life Sciences NV Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

ATAI Life Sciences NV's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.252 + 17.301) / 269.119
=0.07

ATAI Life Sciences NV's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.224 + 18.918) / 247.591
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ATAI Life Sciences NV  (FRA:9VC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


ATAI Life Sciences NV Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of ATAI Life Sciences NV's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


ATAI Life Sciences NV (FRA:9VC) Business Description

Traded in Other Exchanges
Address
Wallstraße 16, Berlin, BB, DEU, 10179
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

ATAI Life Sciences NV (FRA:9VC) Headlines

No Headlines